Mediclinic Panorama and Department of Obstetrics and Gynaecology, Stellenbosch University, South Africa.
Best Pract Res Clin Endocrinol Metab. 2024 Jan;38(1):101782. doi: 10.1016/j.beem.2023.101782. Epub 2023 May 9.
A continuous process of bone turnover is central to bone health and strength. If bone resorption exceeds bone formation, bone strength deteriorates with resultant fractures. Osteoporosis is defined by a fracture or bone mineral density. The lack of ovarian estrogen after menopause causes a significant loss in bone strength, placing women at higher risk of osteoporosis. The probability of future fractures can be calculated by identifying risk factors in all menopausal women. Preventive action starts with a bone-friendly lifestyle. The need for and type of interventive medication can best be determined by classifying fracture risk as low, high, or very high using a combination of fracture history, bone mineral density, 10-year fracture probability or country-specific values. As osteoporosis is an incurable disease, treatment should be seen as a lifelong strategy consisting of the correct sequencing of available bone-specific drugs and appropriate drug-free periods when applicable.
骨转换的持续过程是骨骼健康和强度的核心。如果骨吸收超过骨形成,骨强度就会恶化,导致骨折。骨质疏松症是由骨折或骨密度定义的。绝经后卵巢雌激素的缺乏会导致骨强度显著丧失,使女性面临更高的骨质疏松症风险。通过识别所有绝经后妇女的风险因素,可以计算出未来骨折的概率。预防措施始于一种有益于骨骼的生活方式。通过结合骨折史、骨密度、10 年骨折概率或特定国家的值,将骨折风险分类为低、高或非常高,可最好地确定干预药物的必要性和类型。由于骨质疏松症是一种无法治愈的疾病,因此应将治疗视为一种终生策略,包括正确排列可用的骨特异性药物和在适用时进行适当的无药物治疗期。
Best Pract Res Clin Endocrinol Metab. 2024-1
Maturitas. 1996-3
Ont Health Technol Assess Ser. 2006
Obstet Gynecol. 1990-4
BMC Womens Health. 2025-8-26
Medicine (Baltimore). 2025-7-11
Stem Cells Transl Med. 2025-6-25